skip to Main Content

5th Annual Risk Management and Pharmacovigilance Summit

18 - 20 September 2018, Vienna

Summit as every year will create great atmosphere for PV professionals to network and discuss current issues in the drug safety world. You will hear about all the necessary topics related to the new updates in regulatory, new techniques in digital pharmacovigilance, real examples of benefit-risk evaluation and signal detection, how to go through the inspection, patient support programmes and patient centricity, and many more

Request Full Programme Register Online

 SUMMIT WILL HOST SPEAKERS FROM THE WORLD’S LEADING COMPANIES

See Sample of Key Note Speakers and Their Case Studies.

Simon
ASHWORTH

VP, EU QPPV and Head EU Compliance, Marketed Products and PV Affiliate Relations

Rob
VAN MAANEN

Senior Medical Director, Medical Science

Andrea
YSANDER

EU QPPV and Head Risk Management & Pharmacovigilance Excellence

Monica
MARCANO

Director Cluster Safety Lead West Europe (France, Portugal & Spain)

Diogo
LOPES

Head of Global PV System &
Standards

Attila
OLAH

Head Global Pharmacovigilance, QPPV

EXPERIENCE BASED CASE STUDIES

Adverse Event Reporting from Social Media

With the increasing popularity of social media, online forum discussions are becoming increasingly significant sources of information about drug use.

Pfizer

Navigating through PV Inspections - from announcement to CAPA

The current practice of Inspection of PV system gives an overview of how to navigate through the preparation and conduct of a PV Inspection as well as responding to observations, including corrective/preventive action (CAPA) plans.

Boehringer Ingelheim

Cross-functional Safety Governance

One year after implementing a new safety governance model in a global mid-sized pharma company.

Grünenthal Group

HOT CONFERENCE TOPICS

Will Be Discussed

  • Navigating through PV inspections – from announcement to CAPA
  • Latest trends in Adverse Event Reporting from Social Media
  • Implementation of GVP Rev 2 – Actual experience
  • Multi Criteria Decision Analysis in drug development – practical examples from a development program
  • Could be Pharmacovigilance considered as a thermometer for business?
  • Enhanced EudraVigilance System – future perspectives
  • Benefit-risk evaluation of anticancer medicinal products at entry into human in a changing environment: a review of EMA/CHMP/205/95 Rev.5 guideline
  • Quantitative benefit-risk assessment and patient centricity
  • Patient Support Programmes and Market Research from PV standpoint

WHAT DELEGATES SAID

About Allan Lloyds Events

 SPONSORS 2018

FOR MORE INFORMATION REQUEST FULL PROGRAMME

See what keynote speakers will be taking part in the exclusive speaking panel.
Explore what Case Studies will be discussed by our senior corporate speakers

 YOU MAY BE INTERESTED IN

5th Annual Risk Management and Pharmacovigilance Summit
will start in
TIME IS RUNNING OUT! DON’T RISK MISSING IT
Back To Top